NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

Can-Fite BioPharma Ltd. (CANF) Stock Analysis

Can-Fite BioPharma Ltd. (CANF) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

CANF

$2.23

−$0.12 (−5.11%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CANF with… →

CANF Key Statistics

As of Sep 4, 2026
Trading
Open
$2.34
Previous Close
$2.35
Day's Range
2.23–2.35
52-Week Range
2.23–13.40
Volume
183.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.04
Valuation
Market Cap
$4.78M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
11.80
EPS (ttm)Profit attributable to each share over the last twelve months.
−10.75
Financials (FY)
Revenue (FY)
$405.00K−39.91%
Net Income (FY)
−$9.83M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.14M
1-Year Return
−82.85%
Dividend and dates
Avg Volume
1.77M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CANF Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−44.25%
2025−87.73%
2024−25.91%
2023−63.93%
2022−52.71%
2021−27.53%
2020−46.06%
2019−82.54%
2018−14.86%
2017−37.82%
2016 (partial year)+8.68%

As of September 4, 2026.

CANF Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$405.00K−$9.83M−2426.7%
2024$674.00K−$7.88M−1169.1%
2023$743.00K−$7.63M−1027.5%
2022$810.00K−$10.17M−1255.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$405.00K—−$9.95M−$9.83M−2426.7%
2024$674.00K—−$8.13M−$7.88M−1169.1%
2023$743.00K—−$8.20M−$7.63M−1027.5%
2022$810.00K—−$10.10M−$10.17M−1255.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CANF Valuation vs Biotechnology Median

Median of 656 stocks
MetricCANFBiotechnology medianvs median
P/S ratio11.8015.2623% below
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Can-Fite BioPharma Ltd. (CANF) carries a market capitalisation of $4.78M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 5.

The 52-week range on file runs from $2.23 to $13.40. CANF last closed at $2.23 on September 4, 2026. That is −$0.12 (−5.11%) against the previous close.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $405.00K. That is −39.91% against the prior fiscal year, when revenue was $674.00K. The same year closed with a net loss of $9.83M. Profit margin runs at 0%. Trailing earnings per share are −10.75.

Across the 4 fiscal years on file, revenue moves from $810.00K in 2022 to $405.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 11.8. On price-to-sales that is 22.71% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −82.85%. Across 10 years the annualized return works out at −55.35%. Beta against the wider market is reported at −0.04. Daily returns over the trailing 10 years annualize to a volatility of 84.2%.

Growth & Income

The record shows no dividend for CANF.

2026 is still running; the price is −44.25% year to date. Across the complete calendar years on file, 2018 returned −14.86% and 2025 returned −87.73%. Of the 9 complete calendar years on file, 0 finished higher.

Peer Comparison

Can-Fite BioPharma Ltd. (CANF) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Can-Fite BioPharma Ltd. CANF $4.78M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Can-Fite BioPharma Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Visit website →